Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Diagnosis and Management of Rheumatoid Arthritis
Daniel Aletaha, Josef S Smolen
JAMA (2018) Vol. 320, Iss. 13, pp. 1360-1360
Closed Access | Times Cited: 1679

Showing 1-25 of 1679 citing articles:

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
Josef S Smolen, Robert Landewé, J. W. J. Bijlsma, et al.
Annals of the Rheumatic Diseases (2020) Vol. 79, Iss. 6, pp. 685-699
Open Access | Times Cited: 2314
Global, regional and national burden of osteoarthritis 1990-2017: a systematic analysis of the Global Burden of Disease Study 2017
Saeid Safiri, Ali‐Asghar Kolahi, Emma Smith, et al.
Annals of the Rheumatic Diseases (2020) Vol. 79, Iss. 6, pp. 819-828
Closed Access | Times Cited: 1285
Update on the Pathomechanism, Diagnosis, and Treatment Options for Rheumatoid Arthritis
Yen‐Ju Lin, Martina Anzaghe, Stefan Schülke
Cells (2020) Vol. 9, Iss. 4, pp. 880-880
Open Access | Times Cited: 687
Global, regional and national burden of rheumatoid arthritis 1990–2017: a systematic analysis of the Global Burden of Disease study 2017
Saeid Safiri, Ali‐Asghar Kolahi, Damian Hoy, et al.
Annals of the Rheumatic Diseases (2019) Vol. 78, Iss. 11, pp. 1463-1471
Closed Access | Times Cited: 640
Management of Rheumatoid Arthritis: An Overview
Andrei-Flavius Radu, Simona Bungău
Cells (2021) Vol. 10, Iss. 11, pp. 2857-2857
Open Access | Times Cited: 616
Scavenger receptor-A is a biomarker and effector of rheumatoid arthritis: A large-scale multicenter study
Fanlei Hu, Xiang Jiang, Chunqing Guo, et al.
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 417
ImmunoPET: Concept, Design, and Applications
Weijun Wei, Zachary T. Rosenkrans, Jianjun Liu, et al.
Chemical Reviews (2020) Vol. 120, Iss. 8, pp. 3787-3851
Open Access | Times Cited: 367
Oral microbiota in human systematic diseases
Xian Peng, Lei Cheng, Yong You, et al.
International Journal of Oral Science (2022) Vol. 14, Iss. 1
Open Access | Times Cited: 341
Early-stage symptomatic osteoarthritis of the knee — time for action
Armaghan Mahmoudian, Stefan Lohmander, Ali Mobasheri, et al.
Nature Reviews Rheumatology (2021) Vol. 17, Iss. 10, pp. 621-632
Closed Access | Times Cited: 270
The gut–joint axis in rheumatoid arthritis
Mario M. Zaiss, Hsin-Jung Wu, Daniele Mauro, et al.
Nature Reviews Rheumatology (2021) Vol. 17, Iss. 4, pp. 224-237
Closed Access | Times Cited: 255
Rheumatoid arthritis
Andrea Di Matteo, Joan M. Bathon, Paul Emery
The Lancet (2023) Vol. 402, Iss. 10416, pp. 2019-2033
Closed Access | Times Cited: 245
Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial
Frances Humby, Patrick Durez, Maya H Buch, et al.
The Lancet (2021) Vol. 397, Iss. 10271, pp. 305-317
Open Access | Times Cited: 231
Signaling pathways in rheumatoid arthritis: implications for targeted therapy
Qian Ding, Wei Hu, Ran Wang, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 204
Current Therapeutic Options in the Treatment of Rheumatoid Arthritis
Birgit Köhler, Janine Günther, Dorothee Kaudewitz, et al.
Journal of Clinical Medicine (2019) Vol. 8, Iss. 7, pp. 938-938
Open Access | Times Cited: 196
An update on the efficacy of anti-inflammatory agents for patients with schizophrenia: a meta-analysis
Nuray Çakici, Nico J.M. van Beveren, G. Judge-Hundal, et al.
Psychological Medicine (2019) Vol. 49, Iss. 14, pp. 2307-2319
Open Access | Times Cited: 178
The association between systemic immune-inflammation index and rheumatoid arthritis: evidence from NHANES 1999–2018
Bo Liu, Jie Wang, Yanyan Li, et al.
Arthritis Research & Therapy (2023) Vol. 25, Iss. 1
Open Access | Times Cited: 151
JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future
Jacopo Angelini, Rossella Talotta, Rossana Roncato, et al.
Biomolecules (2020) Vol. 10, Iss. 7, pp. 1002-1002
Open Access | Times Cited: 148
The immunosuppressive activity of artemisinin‐type drugs towards inflammatory and autoimmune diseases
Thomas Efferth, Franz Oesch
Medicinal Research Reviews (2021) Vol. 41, Iss. 6, pp. 3023-3061
Closed Access | Times Cited: 136
Polymeric microneedle-mediated transdermal delivery of melittin for rheumatoid arthritis treatment
Guangsheng Du, Penghui He, Jiaxuan Zhao, et al.
Journal of Controlled Release (2021) Vol. 336, pp. 537-548
Open Access | Times Cited: 118
Three hematologic/immune system-specific expressed genes are considered as the potential biomarkers for the diagnosis of early rheumatoid arthritis through bioinformatics analysis
Qi Cheng, Xin Chen, Huaxiang Wu, et al.
Journal of Translational Medicine (2021) Vol. 19, Iss. 1
Open Access | Times Cited: 106
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II)
Michelle Petri, Ian N Bruce, Thomas Dörner, et al.
The Lancet (2023) Vol. 401, Iss. 10381, pp. 1011-1019
Closed Access | Times Cited: 101
2022 EULAR points to consider for remote care in rheumatic and musculoskeletal diseases
Annette de Thurah, Philipp Bösch, Andréa Marques, et al.
Annals of the Rheumatic Diseases (2022) Vol. 81, Iss. 8, pp. 1065-1071
Open Access | Times Cited: 96
Functional Hallmarks of Healthy Macrophage Responses: Their Regulatory Basis and Disease Relevance
Katherine M. Sheu, Alexander Hoffmann
Annual Review of Immunology (2022) Vol. 40, Iss. 1, pp. 295-321
Open Access | Times Cited: 96
Nanoenzyme engineered neutrophil-derived exosomes attenuate joint injury in advanced rheumatoid arthritis via regulating inflammatory environment
Lei Zhang, Ziguo Qin, Han Sun, et al.
Bioactive Materials (2022) Vol. 18, pp. 1-14
Open Access | Times Cited: 91
Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study
Léa Hoisnard, Laura Pina Vegas, Rosemary Dray‐Spira, et al.
Annals of the Rheumatic Diseases (2022) Vol. 82, Iss. 2, pp. 182-188
Closed Access | Times Cited: 88
Page 1 - Next Page

Scroll to top